Amneal Total Assets from 2010 to 2025

AMRX Stock

USD 8.43 0.07 0.82%

Amneal Pharmaceuticals, Total Assets yearly trend continues to be fairly stable with very little volatility. Total Assets will likely drop to about 3.2 B in 2025. Total Assets is the total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets. View All Fundamentals

Total Assets

First Reported

2016-12-31

Previous Quarter

3.5 B

Current Value

3.5 B

Quarterly Volatility

1.1 B

Covid

Check Amneal Pharmaceuticals, financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Amneal Pharmaceuticals,'s main balance sheet or income statement drivers, such as Depreciation And Amortization of 154.9 M, Interest Expense of 254.3 M or Selling General Administrative of 281.2 M, as well as many indicators such as Price To Sales Ratio of 0.48, Dividend Yield of 0.096 or PTB Ratio of 50.74. Amneal financial statements analysis is a perfect complement when working with Amneal Pharmaceuticals, Valuation or Volatility modules.

Check out the analysis of Amneal Pharmaceuticals, Correlation against competitors.

Latest Amneal Pharmaceuticals,'s Total Assets Growth Pattern

Below is the plot of the Total Assets of Amneal Pharmaceuticals, Class over the last few years. Total assets refers to the total amount of Amneal Pharmaceuticals, assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Amneal Pharmaceuticals, books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. It is the total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets. Amneal Pharmaceuticals,'s Total Assets historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Amneal Pharmaceuticals,'s overall financial position and show how it may be relating to other accounts over time.

View

Last Reported 3.47 B

10 Years Trend

Slightly volatile

Compare to Others All Fundamentals

Total Assets

Timeline

Amneal Total Assets Regression Statistics

	Arithmetic Mean	2,723,600,528
	Geometric Mean	2,462,370,640
	Coefficient Of Variation	42.91
	Mean Deviation	1,075,196,278
	Median	3,160,687,090
	Standard Deviation	1,168,817,368
	Sample Variance	1366134T
	Range	3.3B
	R-Value	0.71
	Mean Square Error	721587T
	R-Squared	0.51
	Significance	0
	Slope	174,809,073
	Total Sum of Squares	20492010.6T

Amneal Total Assets History

	2025	3.2 B
	2024	4 B
	2023	3.5 B
	2022	3.8 B
	2021	3.9 B
	2020	4 B
	2019	3.7 B

Other Fundumenentals of Amneal Pharmaceuticals,

Intangibles To Total Assets

Amneal Pharmaceuticals, Total Assets component correlations

	Total Assets	Total Stockholder Equity	Net Tangible Assets	Net Debt	Retained Earnings	Accounts Payable	Long Term Debt	Net Receivables	Good Will	Short Term Investments	Long Term Debt Total	Capital Surpluse	Total Liab	Short Long Term Debt	Total Current Assets	Treasury Stock	Short Term Debt	Intangible Assets	Common Stock	Property Plant Equipment	Current Deferred Revenue	Net Invested Capital	Net Working Capital	Capital Stock	Long Term Investments
Total Assets		0.84	-0.95	0.9	-0.35	0.66	0.92	0.85	0.93	-0.79	0.94	0.71	0.94	0.41	0.92	0.31	0.45	0.96	0.81	0.74	0.64	0.96	0.83	0.37	-0.22
Total Stockholder Equity	0.84		-0.83	0.69	0.1	0.82	0.75	0.6	0.68	-0.62	0.77	0.32	0.74	0.01	0.7	-0.01	0.05	0.91	0.5	0.64	0.24	0.81	0.79	0.02	0.01
Net Tangible Assets	-0.95	-0.83		-0.96	0.47	-0.72	-0.97	-0.91	-0.93	0.9	-0.98	-0.73	-0.97	-0.46	-0.94	-0.26	-0.51	-0.98	-0.8	-0.87	-0.7	-0.98	-0.85	-0.33	0.26
Net Debt	0.9	0.69	-0.96		-0.62	0.59	0.99	0.95	0.95	-0.95	0.97	0.85	0.98	0.58	0.97	0.37	0.62	0.91	0.86	0.9	0.75	0.95	0.77	0.45	-0.28
Retained Earnings	-0.35	0.1	0.47	-0.62		-0.02	-0.55	-0.67	-0.58	0.62	-0.52	-0.8	-0.55	-0.81	-0.56	-0.48	-0.83	-0.31	-0.65	-0.55	-0.85	-0.47	-0.23	-0.57	0.49
Accounts Payable	0.66	0.82	-0.72	0.59	-0.02		0.63	0.44	0.48	-0.58	0.63	0.21	0.59	0.07	0.49	0.07	0.1	0.79	0.44	0.67	0.18	0.65	0.52	0.07	-0.11
Long Term Debt	0.92	0.75	-0.97	0.99	-0.55	0.63		0.95	0.95	-0.95	0.99	0.82	0.99	0.54	0.98	0.35	0.57	0.94	0.85	0.92	0.73	0.97	0.82	0.42	-0.29
Net Receivables	0.85	0.6	-0.91	0.95	-0.67	0.44	0.95		0.96	-0.89	0.95	0.91	0.96	0.59	0.97	0.4	0.63	0.85	0.86	0.85	0.85	0.93	0.77	0.48	-0.32
Good Will	0.93	0.68	-0.93	0.95	-0.58	0.48	0.95	0.96		-0.83	0.97	0.9	0.98	0.59	0.98	0.42	0.63	0.89	0.9	0.78	0.8	0.96	0.76	0.51	-0.29
Short Term Investments	-0.79	-0.62	0.9	-0.95	0.62	-0.58	-0.95	-0.89	-0.83		-0.9	-0.75	-0.9	-0.5	-0.89	-0.27	-0.54	-0.84	-0.74	-0.95	-0.7	-0.87	-0.77	-0.34	0.27
Long Term Debt Total	0.94	0.77	-0.98	0.97	-0.52	0.63	0.99	0.95	0.97	-0.9		0.83	1.0	0.53	0.98	0.37	0.57	0.95	0.87	0.88	0.74	0.98	0.81	0.44	-0.27
Capital Surpluse	0.71	0.32	-0.73	0.85	-0.8	0.21	0.82	0.91	0.9	-0.75	0.83		0.86	0.79	0.88	0.65	0.81	0.64	0.92	0.71	0.88	0.78	0.53	0.73	-0.45
Total Liab	0.94	0.74	-0.97	0.98	-0.55	0.59	0.99	0.96	0.98	-0.9	1.0	0.86		0.57	0.99	0.4	0.61	0.94	0.89	0.87	0.76	0.98	0.82	0.48	-0.31
Short Long Term Debt	0.41	0.01	-0.46	0.58	-0.81	0.07	0.54	0.59	0.59	-0.5	0.53	0.79	0.57		0.58	0.76	1.0	0.34	0.79	0.5	0.69	0.52	0.24	0.84	-0.77
Total Current Assets	0.92	0.7	-0.94	0.97	-0.56	0.49	0.98	0.97	0.98	-0.89	0.98	0.88	0.99	0.58		0.42	0.62	0.91	0.89	0.84	0.79	0.97	0.84	0.49	-0.32
Treasury Stock	0.31	-0.01	-0.26	0.37	-0.48	0.07	0.35	0.4	0.42	-0.27	0.37	0.65	0.4	0.76	0.42		0.76	0.23	0.77	0.33	0.51	0.37	0.18	0.99	-0.8
Short Term Debt	0.45	0.05	-0.51	0.62	-0.83	0.1	0.57	0.63	0.63	-0.54	0.57	0.81	0.61	1.0	0.62	0.76		0.38	0.82	0.53	0.73	0.56	0.28	0.84	-0.76
Intangible Assets	0.96	0.91	-0.98	0.91	-0.31	0.79	0.94	0.85	0.89	-0.84	0.95	0.64	0.94	0.34	0.91	0.23	0.38		0.76	0.83	0.59	0.97	0.86	0.29	-0.21
Common Stock	0.81	0.5	-0.8	0.86	-0.65	0.44	0.85	0.86	0.9	-0.74	0.87	0.92	0.89	0.79	0.89	0.77	0.82	0.76		0.75	0.8	0.86	0.62	0.82	-0.61
Property Plant Equipment	0.74	0.64	-0.87	0.9	-0.55	0.67	0.92	0.85	0.78	-0.95	0.88	0.71	0.87	0.5	0.84	0.33	0.53	0.83	0.75		0.62	0.83	0.69	0.38	-0.31
Current Deferred Revenue	0.64	0.24	-0.7	0.75	-0.85	0.18	0.73	0.85	0.8	-0.7	0.74	0.88	0.76	0.69	0.79	0.51	0.73	0.59	0.8	0.62		0.74	0.61	0.6	-0.52
Net Invested Capital	0.96	0.81	-0.98	0.95	-0.47	0.65	0.97	0.93	0.96	-0.87	0.98	0.78	0.98	0.52	0.97	0.37	0.56	0.97	0.86	0.83	0.74		0.88	0.45	-0.36
Net Working Capital	0.83	0.79	-0.85	0.77	-0.23	0.52	0.82	0.77	0.76	-0.77	0.81	0.53	0.82	0.24	0.84	0.18	0.28	0.86	0.62	0.69	0.61	0.88		0.22	-0.29
Capital Stock	0.37	0.02	-0.33	0.45	-0.57	0.07	0.42	0.48	0.51	-0.34	0.44	0.73	0.48	0.84	0.49	0.99	0.84	0.29	0.82	0.38	0.6	0.45	0.22		-0.82
Long Term Investments	-0.22	0.01	0.26	-0.28	0.49	-0.11	-0.29	-0.32	-0.29	0.27	-0.27	-0.45	-0.31	-0.77	-0.32	-0.8	-0.76	-0.21	-0.61	-0.31	-0.52	-0.36	-0.29	-0.82

Click cells to compare fundamentals

About Amneal Pharmaceuticals, Financial Statements

Amneal Pharmaceuticals, investors use historical fundamental indicators, such as Amneal Pharmaceuticals,'s Total Assets, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Amneal Pharmaceuticals,. Please read more on our technical analysis and fundamental analysis pages.

	Last Reported	Projected for Next Year
Total Assets	4 B	3.2 B
Intangibles To Total Assets	0.39	0.26

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

CRM	Salesforce
C	Citigroup
GM	General Motors

Additional Tools for Amneal Stock Analysis

When running Amneal Pharmaceuticals,'s price analysis, check to measure Amneal Pharmaceuticals,'s market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Amneal Pharmaceuticals, is operating at the current time. Most of Amneal Pharmaceuticals,'s value examination focuses on studying past and present price action to predict the probability of Amneal Pharmaceuticals,'s future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Amneal Pharmaceuticals,'s price. Additionally, you may evaluate how the addition of Amneal Pharmaceuticals, to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC